{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/67fbe5f67b4fe9379bcfb2cf/688cec26be8bca0ca269aaac?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Episode 3 (BONUS): Crimes Against Innovation - Gender Bias in Trials vs. The Five-to-Ten-Year Promise","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/67fbe5f67b4fe9379bcfb2cf/1754065680641-ce9ac886-d945-4afc-8cd3-59f11e9f6480.jpeg?height=200","description":"<p>In the darkened corridors of laboratories and the silent pages of medical journals, there are stories rarely spoken about—tales of brilliance that burned too bright, and ideas that strayed into catastrophe. This is—<em>Crimes Against Innovation</em>.</p><p>&nbsp;</p><p>Laurence Woollard and Dr. Emma Lane debate two pressing issues in healthcare: the under-representation of women in clinical trials and the misleading timelines often promised for new treatments. Host Nicola Hill listens to both sides and selects the most impactful “crime” against innovation.</p><p>&nbsp;</p><p>This podcast is produced and funded by UCB.</p><p>Hosted on Acast. See <a href=\"https://acast.com/privacy\" rel=\"noopener noreferrer\" target=\"_blank\">acast.com/privacy</a> for more information.</p><p>&nbsp;</p><p>IE-OT-2500003 – July 2025</p>","author_name":"UCB Biopharma "}